New drug hopes to curb rare genetic obesity

NCT ID NCT07220772

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called mibavademab in people with a rare form of obesity caused by a faulty leptin gene. The drug aims to help control hunger and body weight. Only 4 participants will be enrolled to see how well it works and if it is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mibavademab (a leptin receptor agonist)

What this could lead to

If it works, this could provide a treatment option for people with a rare form of obesity caused by a faulty leptin gene.

What could go wrong

This is a very small early-phase trial with only 4 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MONOGENIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

inherited obesity morbid obesity obesity due to congenital leptin deficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ULM University Medical Centre

    RECRUITING

    Ulm, 89075, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••